Caffeine, in the dose usualiy recommended (12-5 mg/kg loading dose and 3 mg/kg daily maintenance), and a higher dose regimen (25 mg/kg loading and 6 mg/kg daily maintenance), was compared with theophylline (7.5 mg/kg loading and 3 mg/kg thrice daily maintenance). The study was a randomised controiled trial in the treatment of a group of 44 infants of less than 31 weeks' gestation (mean gestational age 28.3 weeks) who were suffering from frequent apnoeic attacks. AU three regimens produced a significant reduction in apnoeic attacks within 24 hours, but only the higher dose caffeine and theophyfline groups showed a significant improvement in apnoea within eight hours.
Neonatal apnoea is a common problem: it occurs in 25% of infants under 2500 g and 80% of infants under 1000 g.1 2 With smaller babies now forming a large percentage of the population of neonatal intensive care units, the management of neonatal apnoea is an important part of the clinical workload.
The methylxanthines-theophylline (and aminophylline) and caffeine-are widely used for the treatment of this condition.3 Theophylline has been the drug most commonly used to treat neonatal apnoea in the UK. 4 5 Caffeine, however, has many potential advantages: it has a higher therapeutic ratio, it is absorbed more reliably when administered enterally and has a longer half life, thus enabling the drug to be administered only once daily. 6 Caffeine has also been shown to be effective in apnoeic infants who are unresponsive to theophylline. 7 Comparisons of the two drugs have been reported before,"'0 but these studies have Authority.
Results
Over a two year period 44 infants were entered into the study. Of the 44 infants, 32 (73%) had previously been ventilated and 43 (98%) were still oxygen dependent at the time of entry to the study. Twenty six infants (59%) were boys and 37 (84%) were white.
Although every attempt was made to exclude other causes of apnoea, eight infants were subsequently found to have other problems and it became clear that their apnoeic attacks were secondary to these other diagnoses: four infants had proven infection (pneumonia and septicaemia with positive blood cultures), two infants had significant neurological abnormality (bilateral periventricular leucomalacia with subsequent abnormal neurological development) and two had severe oesophageal reflux (as demonstrated by an intraoesophageal pH probe. 12 Table 1 shows the characteristics of the infants in the trial. There were no significant differences between the groups in weight, gestational age, or postnatal age and the sex distribution of the infants within the groups showed an approximately equal male to female ratio.
RESPONSE TO TREATMENT
The number of apnoeas (over a 24 hour period) decreased dramatically over two days from the start of treatment in all three groups, but was most significant in the high dose caffeine and theophylline groups.
As can be seen in table 2, which includes the results from all infants entered, the number of apnoeas/day was reduced by a third within 24 hours by treatment with standard dose caffeine. It was, however, reduced by over 50% by the higher dose caffeine and theophylline treatments within the same time period. Although a further reduction was observed in the standard dose caffeine group by 48 hours, some infants in the other groups had, by then, had their apnoeas eliminated completely.
We defined successful treatment as a >50% reduction in the number ofapnoeas (as measured over an eight hour period). Only one infant, other than those whose apnoea was retrospectively found to be secondary to another diagnosis, failed to respond within 48 hours of the start of treatment. The response to treatment is illustrated in table 3: those infants who subsequently had other pathology are excluded, rather than being described as 'failures'.
In group A only four of the 12 infants responded to treatment within eight hours.
Caffeine or theophylline for neonantal apnoea? In group C 11 of the 12 infants responded to treatment within eight hours. Another had responded by 48 hours. There were no failures in this group either.
All eight infants who were retrospectively excluded failed to respond with a >50% reduction in apnoeas within 48 hours of starting treatment. Three of the infants who responded to treatment also had other problems: two with periventricular leucomalacia, both in group C, and one with oesophageal reflux in group B. The two with periventricular leucomalacia, however, had unilateral lesions (and a better neurological outcome than those with bilateral lesions who were excluded); and the infant with oesophageal reflux appeared to have less severe reflux, although it may have remained a cause of apnoea (he had a >50% reduction in apnoeas within eight hours, but then persisted with a small number of severe apnoeic attacks each day).
PLASMA DRUG CONCENTRATIONS The figure shows the plasma drug concentrations in the three treatment groups on the first, third, and fifth day after starting treatment (approximately 24, 72, and 120 hours after starting treatment respectively). The mean (SD) plasma concentrations of caffeine in group A on days 1, 3, and 5 were 15-43 (5-11), 15-31 (3-93), and 15-81 (2-90) mg/l respectively. In group B the plasma concentrations of caffeine were: 30-42 (4-05), 32-92 (4-88), and 33-36 (5-27) mg/I. The plasma concentrations of theophylline in group C were: 10-87 (3-52), 14-96 (6-00), and 17-22 (3-19) mg/I.
Over the 10 days during which plasma drug concentrations were monitored, 69% of the measurements on infants in group A showed drug concentrations in the desired range (caffeine 13-20 mg/i), and 73% of the assays on infants in group B were in the desired range (caffeine 26-40 mg/i). In contrast, only 56% of Days after starting treatment Plasma drug concentrations, shown as mean (SD). Group A: standard dose caffeine; group B: higher dose caffeine, and group C: theophylline.
the measurements on infants in group C showed plasma drug concentrations in the desired range (theophylline 13-20 mg/i). SIDE 
EFFECTS
Plasma concentrations of theophylline >20 mg/l were associated with a persistent tachycardia (of > 195 bpm), necessitating a dosage reduction, in two infants. Five of the 12 infants in group C required dosage adjustments, or individual dose omissions on at least two occasions, because of a tachycardia of >195 bpm. Only one of the infants in group A, and none of the infants in group B, needed dosage adjustments because of tachycardia. Apart from this one infant whose tachycardia may have been attributable to treatment, no side effects were apparent with caffeine, even when an error occurred in calculation of the caffeine dose (on the fourth day of treatment in one child), and a plasma concentration of 68 mg/l was measured.
The maximum effect on heart rate (the average of all 24 on-the-hour recordings by nursing staff expressed as bpm) was observed on the fourth day of treatment, with a mean rise in heart rate of 3 bpm and 5 bpm in groups A and B (p<005 on paired t test), and a mean rise in heart rate of 12 bpm in group C (p<0-01).
There was no appreciable difference between the sodium intake, urinary sodium, or fractional sodium excretion of the three groups over the 10 day period. Any natriuretic (diuretic) effect of the medication was probably masked by the high sodium loss which is commonly observed in the urine in infants of these gestations.
Although these drugs in higher doses are reputed to have side effects such as glucose intolerance and 'jitteriness', we observed no such problems. In fact, no serious side effect was attributed to medication in any treatment group.
Discussion
Our study confirmed the efficacy of the methylxanthine drugs, caffeine and theophylline, in the treatment of neonatal apnoea. However, unlike previous reports,3 81O our study is based on infants of lower gestational age (less than 31 weeks); these infants were oxygen dependent. Furthermore, there is no previous information on the response rate in relation to caffeine dosage.
Our results clearly showed a significant rapid reduction in apnoeic attacks within eight hours in infants receiving higher doses of caffeine (plasma concentration approximately 30 mg/l) and theophylline. A rapid response to treatment is valuable and often desirable as intubation or reintubation for ventilation may be avoided.
Despite using a higher caffeine dose, the plasma drug concentrations in all infants were well within the reported therapeutic range.3 Our highest caffeine concentration was 68 mg/l. None of our infants on the higher dose of caffeine suffered any adverse side effects. Anyway, side effects such as glucose intolerance, appreciable tachycardia (>200 bpm) and 'jitteriness' are thought to be rare with plasma caffeine concentrations below 80 mg/l.
In our experience plasma caffeine concentrations were more likely to fall within the predicted range than theophylline, when the drugs were given orally, suggesting better absorption of caffeine. In addition, the known longer half life of caffeine and its higher therapeutic ratio, enable fewer blood tests when using caffeine to treat neonatal apnoea.
In conclusion, our study has shown that caffeine (in the higher dose studied) and theophylline (in a standard dosage) are effective in reducing apnoeic attacks within eight hours, even in oxygen dependent infants of less than 31 weeks' gestational age. However, we recommend the use of caffeine because of the many advantages of this drug over theophylline.
Our current practice is to treat symptomatic babies with the higher dose caffeine schedule described here, and to measure plasma concentrations of caffeine only if there is inadequate clinical response.
